JP7597722B2 - キナゾリノン化合物 - Google Patents

キナゾリノン化合物 Download PDF

Info

Publication number
JP7597722B2
JP7597722B2 JP2021549941A JP2021549941A JP7597722B2 JP 7597722 B2 JP7597722 B2 JP 7597722B2 JP 2021549941 A JP2021549941 A JP 2021549941A JP 2021549941 A JP2021549941 A JP 2021549941A JP 7597722 B2 JP7597722 B2 JP 7597722B2
Authority
JP
Japan
Prior art keywords
disease
compound
mmol
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523383A5 (https=
JP2022523383A (ja
Inventor
ビンウェイ ルー
Original Assignee
セレピュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレピュート インコーポレイテッド filed Critical セレピュート インコーポレイテッド
Publication of JP2022523383A publication Critical patent/JP2022523383A/ja
Publication of JP2022523383A5 publication Critical patent/JP2022523383A5/ja
Application granted granted Critical
Publication of JP7597722B2 publication Critical patent/JP7597722B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021549941A 2019-02-27 2020-02-26 キナゾリノン化合物 Active JP7597722B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811471P 2019-02-27 2019-02-27
US62/811,471 2019-02-27
PCT/US2020/019942 WO2020176652A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Publications (3)

Publication Number Publication Date
JP2022523383A JP2022523383A (ja) 2022-04-22
JP2022523383A5 JP2022523383A5 (https=) 2023-03-06
JP7597722B2 true JP7597722B2 (ja) 2024-12-10

Family

ID=72238692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549941A Active JP7597722B2 (ja) 2019-02-27 2020-02-26 キナゾリノン化合物

Country Status (9)

Country Link
US (1) US12454514B2 (https=)
EP (1) EP3930837A4 (https=)
JP (1) JP7597722B2 (https=)
KR (1) KR20210139279A (https=)
CN (1) CN113747943A (https=)
AU (1) AU2020228374A1 (https=)
CA (1) CA3131294A1 (https=)
IL (1) IL285805A (https=)
WO (1) WO2020176652A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038051A1 (en) 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
US20150017262A1 (en) 2011-04-19 2015-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibition of dynamin related protein 1 to promote cell death
JP7170341B2 (ja) 2017-09-13 2022-11-14 セレピュート インコーポレイテッド 新規低分子化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
WO2013025508A1 (en) * 2011-08-12 2013-02-21 Southern Research Institute Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20190307749A1 (en) * 2018-04-10 2019-10-10 Texas Tech University System Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038051A1 (en) 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US20150017262A1 (en) 2011-04-19 2015-01-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibition of dynamin related protein 1 to promote cell death
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
JP7170341B2 (ja) 2017-09-13 2022-11-14 セレピュート インコーポレイテッド 新規低分子化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASSIDY-STONE, A. ET AL，Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization，Developmental Cell，2008年，14(2)，193-204

Also Published As

Publication number Publication date
US20220162172A1 (en) 2022-05-26
US12454514B2 (en) 2025-10-28
AU2020228374A1 (en) 2021-09-23
WO2020176652A1 (en) 2020-09-03
EP3930837A4 (en) 2022-10-05
KR20210139279A (ko) 2021-11-22
IL285805A (en) 2021-10-31
JP2022523383A (ja) 2022-04-22
CN113747943A (zh) 2021-12-03
CA3131294A1 (en) 2020-09-03
EP3930837A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
TWI891621B (zh) 一種噠嗪類衍生物抑制劑、其製備方法和應用
EP4570794A1 (en) Heterocyclic compound for inhibiting and/or inducing degradation of kras protein
WO2022007841A1 (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
TWI623533B (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
TWI617546B (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
WO2022033410A1 (zh) 一种egfr抑制剂及其制备方法和应用
WO2022105908A1 (zh) Egfr抑制剂及其制备方法与在药学上的应用
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
US9724331B2 (en) Use of maleimide derivatives for preventing and treating leukemia
WO2020259703A1 (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
TW202317563A (zh) 一種聯苯類衍生物抑制劑的晶型及其製備方法
CN111196814A (zh) 芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用
TW201835079A (zh) ６－吡唑－［１，２，４］三唑並［４，３－α］吡啶－３－醯胺類衍生物、其製備方法及其在醫藥上的應用
JP7597722B2 (ja) キナゾリノン化合物
KR20170108150A (ko) 항암 화합물
JP7036332B2 (ja) キノリン又はキナゾリン化合物及びその応用
CN119947717A (zh) 尿石素衍生物的治疗用途
TW202039508A (zh) 作為sting促效劑之三環化合物及其製備方法及醫藥用途
CN113861195B (zh) 一种多稠环egfr抑制剂及其制备方法和应用
CN114072399B (zh) 芳甲酰胺类化合物及其制备方法和医药用途
WO2023030335A1 (zh) 作为tyk2/jak1假激酶结构域抑制剂的化合物及合成和使用方法
WO2022237825A1 (zh) 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
TWI918767B (zh) 含二并環類衍生物抑制劑自由鹼的晶型及其製備方法和應用
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230224

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231016

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241128

R150 Certificate of patent or registration of utility model

Ref document number: 7597722

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150